Comparative Pharmacology
Head-to-head clinical analysis: CRESTOR versus ROSUVASTATIN CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRESTOR versus ROSUVASTATIN CALCIUM.
CRESTOR vs ROSUVASTATIN CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Rosuvastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, upregulates LDL receptors, and enhances clearance of LDL from plasma.
Oral, 5-40 mg once daily. Initial dose typically 10-20 mg; max 40 mg.
Oral, 5-40 mg once daily, starting at 5-10 mg, titrated based on LDL-C response, maximum 40 mg/day.
None Documented
None Documented
The terminal elimination half-life is approximately 19 hours (range 13–20 hours). This long half-life allows once-daily dosing and provides sustained HMG-CoA reductase inhibition.
Terminal elimination half-life is approximately 19 hours, which supports once-daily dosing and allows for sustained HMG-CoA reductase inhibition.
Approximately 90% of rosuvastatin is eliminated in feces (as unchanged drug and metabolites), and about 10% is excreted in urine (mainly as unchanged drug). Biliary excretion is the primary route for elimination of metabolites.
Approximately 90% of the absorbed dose is excreted in feces via biliary elimination, with the remaining 10% excreted renally as unchanged drug and metabolites. Unchanged rosuvastatin accounts for about 5% of the dose in urine.
Category C
Category D/X
Statin
Statin